安全监测

降纤酶关键质量属性研究*

展开
  • 1.四川大学生物治疗国家重点实验室,成都 610044;
    2.四川省药品检验研究院 国家药品监督管理局疫苗及生物制品质量控制与评价重点实验室,四川省药品监督管理局生物制品质量监测与风险评估重要实验室,成都 611731
第一作者 Tel:(028)87877146;E-mail:zoujian2111@ 126.com
** 李 炯 Tel:(028)85164063;E-mail:ligionghh@scu.edu.cn
李 炎 Tel:(028)87877114;E-mail: 34904523@qq.com

收稿日期: 2023-06-13

  网络出版日期: 2024-06-21

基金资助

* 国家药典委员会标准提高课题(2018H060)

Study on key quality properties of defibrase*

Expand
  • 1. State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610044, China;
    2. Sichuan Institute for Drug Control, NMPA Key Laboratory for Quality Control and Evaluation of Vaccines and Biological Products, SCMPA Key Laboratory for Quality Control Monitoringund Risk Assessment of Biological Products, Chengdu 611731, China

Received date: 2023-06-13

  Online published: 2024-06-21

摘要

目的:通过对降纤酶鉴别、纯度、分子量、等电点、N端序列、比活性6个方面关键质量属性的表征,为后续标准提高提供依据。方法:采用SDS-PAGE电泳法分析不同来源的蛇毒原料;采用紫外-可见分光光度法、SDS-PAGE电泳法、体积排阻色谱和反相超高效液相色谱法、基质辅助激光解析电离-飞行时间质谱法、等电聚焦电泳法、“edman”N端测序法以及凝固法和生色底物法对不同企业提供的降纤酶进行测定和分析。结果:不同来源的尖吻蝮蛇蛇毒蛋白组成基本一致,尖吻蝮蛇蛇毒和白眉蝮蛇蛇毒蛋白质组成差异较大。降纤酶对苯甲酰-L-精氨酸甲酯盐酸盐最大吸收波长为247 nm,对苯甲酰-L-精氨酸乙酯盐酸盐最大吸收波长为254 nm,但对苯甲酰-DL-精氨酰对硝基苯胺无水解作用。降纤酶能完全水解纤维蛋白原α肽链,活性受到苯甲基磺酰氟、二硫苏糖醇和对氨基苯甲醚的抑制。尺寸排阻高效液相色谱法降纤酶纯度测定结果高于反向超高效液相色谱法,前者为99.9%,后者为95.4%。SDS-PAGE电泳法测降纤酶完整分子量受标准品线性范围的影响,采用10~250 kDa范围的标准品点拟合,降纤酶完整分子量为(42.1±1.6)kDa;采用10~100 kDa范围的标准品点拟合,降纤酶分子量为(38.4±1.3)kDa。MALDI-TOF-MS法测得降纤酶完整分子量为(33.3±0.5)kDa,脱糖基分子量为(28.8±0.02)kDa。降纤酶pI值在3.0~4.0之间,N端序列为VIGGVECDINEHRFL。凝固法和生色底物法测比活性相关性显著(P<0.01),但凝固法结果高于生色底物法。结论:不同企业提供的降纤酶的6个方面的关键质量属性基本一致。现行降纤酶药品国家标准中鉴别、纯度、分子量等项目有待进一步增修订。

本文引用格式

邹剑, 李炯, 杨金亮, 李炎, 杨蕾, 马晶, 袁月 . 降纤酶关键质量属性研究*[J]. 药物分析杂志, 2023 , 43(12) : 2137 -2146 . DOI: 10.16155/j.0254-1793.2023.12.20

Abstract

Objective: To provide the basis for the improvement of the standard by characterizing the key quality attributes of defibrase in six aspects: identification, purity, molecular weight, isoelectric point, N-terminal sequence and specific activity. Methods: The raw materials of snake venom from different sources were analyzed by SDS-PAGE electrophoresis. Ultraviolet-visible spectrophotometry, SDS-PAGE electrophoresis, size exclusion chromatography and reverse phase ultra-high performance liquid chromatography, matrix assisted laser desorption ionization-time of flight mass spectrometry, isoelectrofocusing electrophoresis, “edman” N-terminal sequencing method, coagulation method and color substrate method were used to determine and analyze the defibrase supplied by different manufacturers. Results: The venom composition of Deinagkistrodon acutus from different sources was basically the same, and the venom composition of Deinagkistrodon acutus was different from that of Gloydius ussuriensis. The maximum absorption wavelength of defibrase was 247 nm for benzoyl-L-arginine methyl ester hydrochloride and 254 nm for benzoyl-L-arginine ethyl ester hydrochloride, but no hydrolysis was observed for benzoyl-DL-arginine p-nitroaniline. Defibrase could completely hydrolyze fibrinogen α peptide chain, and the activity is inhibited by phenylmethylsulfonyl fluoride, dithiothreitol and p-aminoanisole. The purity of defibrase by size exclusion HPLC and RP-UPLC were 99.9% and 95.4%, respectively. The complete molecular weight of defibrase measured by SDS-PAGE electrophoresis was affected by the linear range of standard substance. The complete molecular weight of defibrase was (42.1±1.6)kDa by standard point fitting in the range of 10-250 kDa, as well as (38.4±1.3)kDa by standard point fitting in the range of 10-100 kDa. The molecular weight of defibrase was (33.3±0.5)kDa and that of deglycosylation was (28.8±0.02)kDa by MALDI-TOF-MS method. The pI values of defibrase were between 3.0 and 4.0, and the N-terminal amino acid sequence was VIGGVECDINEHRFL. The specific activity of coagulation method was significantly correlated with that of chromogenic substrate method (P<0.01), but the results of coagulation method were higher than that of chromogenic substrate method. Conclusion: The six key quality attributes of defibrase provided by different manufacturers were basically the same. The identification, purity, molecular weight and other items in the current national standards for defibrase need to be further revised.

参考文献

[1] 高晶, 刘秀琴, 郭玉璞. 降纤制剂的研究和临床应用新进展[J]. 中华神经科杂志2001, 34(5):305
GAO J, LIU XQ, GUO YP. Research progress and clinical application of defibrination preparations [J]. Chin J Neurosct, 2001, 34(5):305
[2] 国家药品标准 化学药品地方标准上升国家标准.第16册[S]. 2000: 88
National Drug Standards National Standards for Chemicals Promoted from Local Standards. Vol 16 [S]. 2000: 88
[3] 毛歆,梁成罡,杨化新. 降纤酶注射剂的检测分析[J]. 药物分析杂志,2010, 30(2):181
MAO X, LIANG CG, YANG HX. Detection and analysis of defibrase injection [J]. Chin J Pharm Anal,2010,30 (2):181
[4] 李炎,林涛,王叔桥. 降纤酶质量研究[J]. 中国药师,2015,18(10):1695
LI Y, LIN T, WANG SQ. Study on the quality of defibrase [J]. Chin Pharm, 2015,18 (10):1695
[5] 郑丽君,何国振. 注射用降纤酶生产的质量控制[J]. 广东药学,2001,11(1):23
ZHENG LJ, HE GZ. Quality control of defibrase production for injection [J]. Guangdong Pharm,2001,11(1):23
[6] 中华人民共和国药典2020年版.四部[S]. 2020:69
ChP 2020.Vol Ⅳ [S]. 2020: 69
[7] 管利丰,戚正武.蝮蛇蛇毒类凝血酶的研究Ⅰ:分离提纯及理化性质的鉴定[J]. 生物化学与生物物理学报,1982,14(4):1
GUAN LF, QI ZW. Study on Thrombin from snake venom of Agkistrodon halys pallas Ⅰ: isolation, purification and identification of physicochemical properties [J]. Acta Biochim Biophys Sin, 1982, 14(4):1
[8] 中华人民共和国药典2020年版. 四部[S]. 2020:39,106
ChP 2020.Vol Ⅳ [S]. 2020: 39,106
[9] KOH A YS, KH CHUNG. Biochemical characterization of a thrombin-like enzyme and a fibrinolytic serine protease from snake (Agkistrodon saxatilis) venom[J]. Toxicon, 2001, 39:555
[10] 冯华,季楠.蛇毒血凝酶临床应用指南[M]. 北京:中国协和医科大学出版社,2017:17
FENG H, JI N. Guidelines for Clinical Application of Snake Venom Hemagglutinin [M]. Beijing:China Union Medical University Press, 2017:17
[11] BELL WR. Defibrinogenating enzymes[J]. Drugs, 1997, 3:18
[12] CASTRO HC. Snake venom thrombin-like enzymes: from reptilase to now[J]. Cell Mol Life Sci, 2004, 61:843
[13] 孙德军,闫琪. 中国长白山乌苏里蝮蛇降纤酶基因克隆和结构分析 [J]. 吉林大学学报,2003,29(2):138
SUN DJ, YAN Q. Cloning and structure analysis of degenerase gene of Agkistrodon Usuli from Changbai mountain, China [J]. J Jilin Univ, 2003, 29(2):138
[14] 孙德军,杨春伟. 岩栖蝮蛇毒腺CDNA文库构建、降纤酶基因克隆和序列分析[J]. 中国生化药物杂志,2005,26(3):151
SUN DJ, YANG CW. CDNA library construction, cloning and sequence analysis of defibroase gene of Adkistrodon viroides [J]. Chin J Biochem Drugs, 2005, 26(3):151
[15] 郭鹏,张服基.中国蝮蛇头骨形态比较及分类学讨论(蛇亚目:蝮亚科)[J]. 动物学研究,1999,20(6):415
GUO P, ZHANG FJ. Comparison of skull morphology and taxonomic discussion of Agkistrodon from China (Ophididae: Viperinae) [J]. Zool Res, 1999, 20 (6):415
[16] SERRANO SMT, MAROUN RC. Snake venom serine proteinases: Sequence homology vs. substrate specificity, a paradox to be solved[J]. Toxicon, 2005, 45:1115
[17] 张艳娇,邹秀敏,陆海宁.注射用降纤酶中间体的活性监控[J]. 广东畜牧兽医科技,2000,25(1):32
ZHANG YJ, ZOU XM, LU HN. Monitoring the activity of defibrase intermediates for injection [J]. Guangdong J Anim Veter Sci, 2000, 25(1):32
[18] 矫筱蔓,王全.反相高效液相色谱法鉴别不同来源降纤酶[J]. 中国药师,2013,16(11):11
JIAO XM, WANG Q. Identification of defibrase from Different sources by reversed-phase high performance liquid chromatography [J]. Chin Pharm, 2013,16(11):11
[19] 郭鹏, 刘芹. 中国蝮蛇[M]. 北京:科学出版社,2021:7
GUO P, LIU Q. Agkistrodon Chinensis [M]. Beijing: Science Press, 2021:7
文章导航

/